Study: NCT02390609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Treatment A) [Reference]
Description: Participants will receive Ibrutinib 560 milligram (mg) (4\*140 mg) capsule as Treatment A under fasted conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Treatment A) [Reference]
Description: Participants will receive Ibrutinib 560 milligram (mg) (4\*140 mg) capsule as Treatment A under fasted conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Treatment A) [Reference]
Description: Participants will receive Ibrutinib 560 milligram (mg) (4\*140 mg) capsule as Treatment A under fasted conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Treatment A) [Reference]
Description: Participants will receive Ibrutinib 560 milligram (mg) (4\*140 mg) capsule as Treatment A under fasted conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Treatment A) [Reference]
Description: Participants will receive Ibrutinib 560 milligram (mg) (4\*140 mg) capsule as Treatment A under fasted conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Treatment A) [Reference]
Description: Participants will receive Ibrutinib 560 milligram (mg) (4\*140 mg) capsule as Treatment A under fasted conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Treatment A) [Reference]
Description: Participants will receive Ibrutinib 560 milligram (mg) (4\*140 mg) capsule as Treatment A under fasted conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Treatment A) [Reference]
Description: Participants will receive Ibrutinib 560 milligram (mg) (4\*140 mg) capsule as Treatment A under fasted conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Treatment A) [Reference]
Description: Participants will receive Ibrutinib 560 milligram (mg) (4\*140 mg) capsule as Treatment A under fasted conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Treatment A) [Reference]
Description: Participants will receive Ibrutinib 560 milligram (mg) (4\*140 mg) capsule as Treatment A under fasted conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Treatment B)
Description: Participants will receive Ibrutinib 560 mg suspension as Treatment B under fasted conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Treatment B)
Description: Participants will receive Ibrutinib 560 mg suspension as Treatment B under fasted conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Treatment B)
Description: Participants will receive Ibrutinib 560 mg suspension as Treatment B under fasted conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Treatment B)
Description: Participants will receive Ibrutinib 560 mg suspension as Treatment B under fasted conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Treatment B)
Description: Participants will receive Ibrutinib 560 mg suspension as Treatment B under fasted conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Treatment B)
Description: Participants will receive Ibrutinib 560 mg suspension as Treatment B under fasted conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Treatment C)
Description: Participants will receive Ibrutinib 560 mg suspension as Treatment C under fed (high-fat) conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Treatment C)
Description: Participants will receive Ibrutinib 560 mg suspension as Treatment C under fed (high-fat) conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Treatment C)
Description: Participants will receive Ibrutinib 560 mg suspension as Treatment C under fed (high-fat) conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Treatment C)
Description: Participants will receive Ibrutinib 560 mg suspension as Treatment C under fed (high-fat) conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Treatment C)
Description: Participants will receive Ibrutinib 560 mg suspension as Treatment C under fed (high-fat) conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Treatment C)
Description: Participants will receive Ibrutinib 560 mg suspension as Treatment C under fed (high-fat) conditions in one of the treatment periods.